EUVIMEDEUVIMED entdecken
Multizentrische Studie

Which allogeneic hematopoietic cell transplant recipients have an increased risk for delayed‐onset clinically significant cytomegalovirus infection after letermovir prophylaxis?

Maria Alejandra Mendoza iD, Eric Bhaimia, Hassan B Alkhateeb, Raymund R Razonable iD, Matthew Thoendel

Transplant Infectious Disease · 2024

DOI: 10.1111/tid.14377 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Transplant Infectious Disease, 2024. Verfasst von Maria Alejandra Mendoza und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections, Antiviral Agents, Transplantation, Homologous. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Cytomegalovirus (CMV) reactivation is one of the most common complications after allogeneic hematopoietic stem cell transplantation (HSCT). Letermovir is approved for CMV prophylaxis among high‐risk recipients. However, delayed‐onset post‐prophylaxis clinically significant CMV infection (csCMVi) has been observed, suggesting the potential for extending letermovir prophylaxis beyond the first one hundred days post‐HSCT.

Methods

Retrospective multicenter cohort study of allogeneic HSCT patients from August 2018 to March 2023. The primary aim of this study was to identify the risk factors at day 100 associated with delayed onset csCMVi, in patients who received letermovir prophylaxis up to day 100. Competing risk analysis was used to evaluate incidence with specific risk factors, using Gray's Test comparing groups for each event.

Results

Among 166 eligible allogeneic HSCT recipients, the most common primary hematological diagnosis was acute myelogenous leukemia (AML) (42.2%). Twenty‐six (15.7%) developed a breakthrough csCMVi. Delayed‐onset csCMVi occurred in 23.5%, at a median time of 133 days after SCT. On multivariate analysis, having a matched unrelated donor (odds ratio [OR] 2.46) and a CMV donor negative/recipient positive status (OR 3.47) were associated with delayed onset csCMVi. In contrast, AML had a lower odd of having delayed‐onset csCMVi (OR 0.23).

Conclusions

Having a matched unrelated donor, a CMV donor negative/recipient positive status, and a non‐AML underlying disease were associated with delayed onset csCMVi. Prospective studies are needed to evaluate whether extended letermovir prophylaxis is beneficial for these patients. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationCytomegalovirus InfectionsAntiviral AgentsTransplantation, HomologousQuinazolinesCytomegalovirusAcetatesHumansMaleRetrospective StudiesMiddle AgedFemaleAdultRisk FactorsAgedIncidenceYoung AdultTransplant RecipientsLeukemia, Myeloid, Acute

Stichwörter der Autor:innen

allogeneiccytomegalovirusletermovir

Substanzen

letermovirAntiviral AgentsQuinazolinesAcetates

Autor:innen und Institutionen

  • Department of Medicine, Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Internal Medicine, Division of Infectious Diseases, Rush University Medical Center, Chicago, Illinois, USA.
  • Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Maria Alejandra Mendoza, Raymund R Razonable

Förderung

  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Mendoza, M. A., Bhaimia, E., Alkhateeb, H. B., Razonable, R. R., & Thoendel, M. (2024). Which allogeneic hematopoietic cell transplant recipients have an increased risk for delayed‐onset clinically significant cytomegalovirus infection after letermovir prophylaxis?. Transplant Infectious Disease. https://doi.org/10.1111/tid.14377

Vancouver

Mendoza MA, Bhaimia E, Alkhateeb HB, Razonable RR, Thoendel M. Which allogeneic hematopoietic cell transplant recipients have an increased risk for delayed‐onset clinically significant cytomegalovirus infection after letermovir prophylaxis?. Transplant Infectious Disease. 2024. doi:10.1111/tid.14377

BibTeX
@article{Mendoza2024,
  author = {Mendoza, Maria Alejandra and Bhaimia, Eric and Alkhateeb, Hassan B and Razonable, Raymund R and Thoendel, Matthew},
  title = {Which allogeneic hematopoietic cell transplant recipients have an increased risk for delayed‐onset clinically significant cytomegalovirus infection after letermovir prophylaxis?},
  journal = {Transplant Infectious Disease},
  year = {2024},
  doi = {10.1111/tid.14377}
}
Kostenlos starten →